• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Intravacc announces results of pre-clinical study of its intranasal COVID-19 vaccine candidate

Intravacc has announced that a pre-clinical study of its intranasal outer membrane vesicle (OMV)-based recombinant spike protein (rSP) vaccine candidate against SARS-CoV-2 nose spray vaccine in hamsters and mice demonstrated complete protection. The company announced in June 2020 that it had partnered with Wageningen Bioveterinary Research and Utrecht University to develop an intranasal vaccine for the prevention of COVID-19. According to Intravacc, its intranasal vaccine candidates “not only induce high mucosal and systemic immune responses, but they are also cheap to manufacture and stay stable at 4°C for many years.”

The pre-clinical study evaluated two two-dose OMV-rSp vaccines, one of which was based on Intravacc’s OMV-click technology. According to Intravacc, the OMV-click vaccine generated significantly higher levels of neutralizing antibodies in mice and slightly higher levels in hamsters than the other candidate. Hamsters that received either vaccine were free of lung lesions seven days post challenge and lost less weight than animals that were unvaccinated or that were vaccinated with OMVs or rSP alone.

Intravacc Director Program Management Dinja Oosterhoff commented, “Our focus is to develop an intranasal COVID-19 vaccine that can induce both a systemic and a mucosal immune response. Mucosal immunity is the first line of defense for respiratory infections and plays an important role in the prevention of transmission of SARS-CoV-2. The preclinical data provides evidence supporting the efficacy potential of our OMV platform for intranasal applications.”

CEO Jan Groen said, “We are very pleased with this pre-clinical data of our intranasal SARS-CoV-2 candidate vaccine. This allows us to move quickly towards an in human combined Phase 1 and 2 clinical trial. Based on historical scientific and clinical data generated at Intravacc, I am convinced that we are well-positioned for the further development of this vaccine. This and previous data clearly demonstrate the value of our OMV-vaccine technology for future development of other preventive and therapeutic vaccines.”

Read the Intravacc press release.

Share

published on April 8, 2021

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews